Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464925) titled 'A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma' on March 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tetragon Biosciences Ltd
Condition:
Glioblastoma Multiforme of Brain
Glioma
Glioblastoma
Intervention:
Drug: GLIX1
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 2026
Target Sample Size: 30
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/s...